IDH1 and central nervous system cancer: Unlike other IDH-mutated tumors such as gliomas, AML cells with high levels of 2-HG were reported to be either more resistant to induction therapy or more sensitive to several other therapies like PARP inhibitors [85] or venetoclax [87].